Bronchodilators on the Exercise Capacity of Bronchiectasis Patients

Launched by UNIVERSITY OF SAO PAULO GENERAL HOSPITAL · Jan 7, 2022

Keywords

ClinConnect Summary

This is a randomized, double-blind, crossover, placebo-controlled trial. Forty clinically stable patients with bronchiectasis (BCE), all sexes, 18 to 59 years, will be evaluated in two non-consecutive days. On the first day, anamnesis, anthropometric evaluation and lung function will be performed, followed by: Quality of Life Questionnaire-Bronchiectasis, Saint George questionnaire, modified Medical Research Council scale and social and economic status. Then, a cardiopulmonary exercise test (CPET) will be performed and after a rest period, a bronchodilator (BD) or placebo randomization will...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All sexes
• • 18 to 59 years
• • Bronchiectasis diagnosis, according to thorax the Computed Tomography (Pasteur et al., 2010)
• • Clinically stable (last 30 days without exacerbation/hospitalization)
• • Air trapping on plethysmography (Residual Volume/Total Lung Capacity\>125%)
• • Smoking Load \<10 pack-years
• Exclusion Criteria:
• • Do not accept to participate
• • Smoking
• • Continuous oxygen use
• • Pulmonary Rehabilitation program in the last 6 months
• • Previous lung resection
• • Uncontrolled cardiovascular disease
• • Other respiratory chronic diseases
• • Neurological or musculoskeletal disorders that limit exercise
• • Cognitive deficits that limit comprehension